A Study of MGC026 in Participants With Advanced Solid Tumors

This study is testing a new drug called MGC026, an antibody-drug conjugate — essentially a targeted missile that delivers chemotherapy directly to cancer cells — in people with advanced solid tumors that have spread or cannot be surgically removed. It is an early-phase trial to find the right dose and understand how safe the drug is. **You may be eligible if...** - You are 18 or older - You have an advanced or metastatic solid tumor, including cancers of the head and neck, lung, bladder, breast, colon, stomach, liver, ovary, cervix, prostate, skin (melanoma), or other types listed in the trial - Your cancer is measurable on imaging scans - You have not previously been treated with any drug targeting B7-H3 or any antibody-drug conjugate with a topoisomerase payload - You are not pregnant or breastfeeding and agree to use effective birth control **You may NOT be eligible if...** - You have a separate active cancer requiring treatment in the last 2 years - You have untreated or progressing brain metastases - You have had a stem cell or organ transplant - You recently had surgery, systemic cancer treatment, or immunotherapy - You have significant heart or lung problems Talk to your doctor to see if this trial is right for you.